Biopharmx Corporatio (BPMX) 0.78 $BPMX BioPharmX to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biopharmx Corporatio (BPMX) 0.78 $BPMX

BioPharmX to Report First Quarter Financial Results on June 14, 2016
PR Newswire - Tue Jun 07, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal first quarter ended April 30, 2016 after the close of trading on Tuesday, June 14, 2016. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PDT/4:30 p.m. EDT.
BPMX: 0.78 (-0.04)

BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effective, Non-hormonal Treatment for FBC
PR Newswire - Mon May 16, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
BPMX: 0.78 (-0.04)

BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
PR Newswire Europe - Mon May 09, 6:02AM CDT
Company is one of a handful of presenters featured during the global conference
BPMX: 0.78 (-0.04)

BioPharmX Corporation Reports Fourth Quarter and Fiscal Year End Financial Results
PR Newswire - Tue Apr 26, 3:10PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the fourth quarter and fiscal year ended January 31, 2016.
BPMX: 0.78 (-0.04)

BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne
PR Newswire - Mon Apr 25, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.
BPMX: 0.78 (-0.04)

BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016
PR Newswire - Wed Apr 13, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal fourth quarter and full year ended January 31, 2016 after the close of trading on Tuesday, April 26, 2016. The company's management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
BPMX: 0.78 (-0.04)

Health Canada Approves BioPharmX Corporation Study of Violet® Iodine
PR Newswire - Mon Apr 04, 7:30AM CDT
BioPharmX engages KGK Synergize, Inc. to manage its Canadian phase 4 study for Violet molecular iodine breast health supplement
BPMX: 0.78 (-0.04)

BioPharmX Corporation Announces Closing Of $4.3 Million Public Offering
PR Newswire - Fri Apr 01, 10:45AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the closing of its previously announced underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock, with a public offering price of $1.20 per share and related warrant. The warrants have an exercise price of $1.20 per share, are exercisable immediately and expire on April 1, 2021. The transaction included participation from existing investors, including investment vehicles of Franklin Advisers.
BPMX: 0.78 (-0.04)

BioPharmX Corporation Announces Pricing Of Public Offering To Raise $4.3 Million
PR Newswire - Tue Mar 29, 8:16AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the pricing of an underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock with a public offering price of $1.20 for one share of common stock and a warrant to purchase 0.5 of a share of common stock. The company expects to receive gross proceeds of approximately $4.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The company has also granted the underwriters a 45 day option to purchase up to an additional 324,000 shares of common stock and/or warrants to purchase up to an additional 162,000 shares of common stock to cover over-allotments, if any.
BPMX: 0.78 (-0.04)

BioPharmX Corporation Announces Proposed Public Offering of Common Stock and Warrants
PR Newswire - Mon Mar 28, 3:05PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
BPMX: 0.78 (-0.04)

BioPharmX Corporation Initiates Post-Market Phase IV Study for Fibrocystic Breast Condition (FBC) and Cyclic Mastalgia
PR Newswire - Tue Mar 22, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for use in dermatology and women's health, today announced it has received institutional review board (IRB) approval to initiate a Phase 4 study of its Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia.
BPMX: 0.78 (-0.04)

BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directors
PR Newswire - Wed Jan 27, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that Craig A. Barbarosh has joined the company's board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee.
BPMX: 0.78 (-0.04)

BioPharmX's BPX-01 topical formulation may offer breakthrough in acne treatment
M2 - Mon Jan 18, 5:24AM CST
Pharmaceutical company BioPharmX (NYSE MKT: BPMX) said on Friday that its research shows that its unique formulation of minocycline, called BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.78 (-0.04)

Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
PR Newswire - Fri Jan 15, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at the 2016 Winter Clinical Dermatology Conference next week shows its unique formulation of minocycline, known as BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.78 (-0.04)

BioPharmX Violet Iodine Mobile Marketing Campaign On Pandora Achieves 25 Times the Average Industry Response
PR Newswire - Tue Jan 12, 7:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX) today announced that its preliminary campaign test results of advertising on Pandora (NYSE: P), the world's most powerful music discovery platform, show that personalized, streaming radio is an innovative, effective way to drive consumer awareness of Violet® iodine, a new breast health supplement for women.
P: 13.35 (+0.42), BPMX: 0.78 (-0.04)

Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.41 (+0.01), XRM: 8.58 (+0.25), TBBK: 5.27 (+0.08), BPMX: 0.78 (-0.04)

BioPharmX Corporation Reports Third Quarter Financial Results
PR Newswire - Mon Dec 14, 3:05PM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the third fiscal quarter ended October 31, 2015.
BPMX: 0.78 (-0.04)

BioPharmX Corporation to Report Third Quarter Financial Results on December 14, 2015
PR Newswire - Fri Dec 11, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal third quarter ended October 31, 2015 after the close of trading on Monday, December 14, 2015. The Company's management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
BPMX: 0.78 (-0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 0

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 326

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 419

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 0

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 269

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

GM Partners with Barclays to Enhance Credit Card Offerings

Updated Category News Views 71

General Motors and Barclays Sign a Strategic Partnership General Motors (NYSE: GM) and Barclays have recently announced a significant long-term partnership that focuses on credit card services. This strategic agreement reflects both companies' commitment to enhancing customer experience and providing innovative financial solutions. Benefits of the New Credit Card...

Continue Reading
Enbridge Inc. Declares 3% Increase in Quarterly Dividend

Updated Category News Views 126

Enbridge Inc. Increases Quarterly Dividend by 3% Enbridge Inc. (TSX: ENB) has made a significant announcement regarding its quarterly dividend. The company declared a quarterly dividend of $0.9425 per common share, signaling a 3% increase from previous rates. This notable hike reflects Enbridge's commitment to shareholder value and marks the thirtieth consecutive year of...

Continue Reading
Jefferies Advises Caution on Biotech-Related CRO Investments

Updated Category News Views 545

CROs Confront Challenges as Biotech Market Slows In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined. Financial Struggles Affects Companies Jefferies has...

Continue Reading
Remarkable Cost Savings with QUELIMMUNE for Pediatric AKI

Updated Category News Views 137

Significant Economic Impact of QUELIMMUNE Therapy SeaStar Medical Holding Corporation (Nasdaq: ICU), a pioneering healthcare company, has recently published a health economic analysis that underscores the substantial financial benefits of its QUELIMMUNE therapy for pediatric patients suffering from Acute Kidney Injury (AKI). The analysis highlights an estimated average...

Continue Reading
SKF Invites Fans to Revitalize Tattoos with Brand Update

Updated Category News Views 228

SKF Invites Fans to Revitalize Tattoos with Brand Update SKF has taken an impactful step to modernize its brand identity, showcasing a fresh and dynamic look aimed at connecting with its audience more effectively. This update marks the company's first significant change to its logo since its inception in 1908, highlighting the dedication to innovation while respecting its...

Continue Reading